MONDAY, APRIL 16
9:30 a.m. to 1:00 p.m.
Session on Ethics in Cancer Research
Balancing Cost and Clinical Benefits of New Anticancer Agents: A Societal Dilemma
Co-Chairpersons: Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Boston, MA, and Walter Wolf, USC School of Pharmacy, Los Angeles, CA
- New anticancer agents: ensuring patient access, Susan D. Desmond-Hellman, Genentech Inc., South San Francisco, CA
- Making cancer a chronic disease: The ethical predicaments of progress?, Alexander M. Capron, University of Southern California, Los Angeles, CA
- The impact of cost-effectiveness analyses on US cancer care, Deborah Schrag, Memorial Sloan-Kettering Cancer Center, New York, NY
- Why is there so much interest in the cost of cancer care?, Neal J. Meropol, Fox Chase Cancer Center, Philadelphia, PA
MONDAY, APRIL 16
10:15 a.m. to 10:30 a.m.
Address by the Director of the National Cancer Institute
- John E. Niederhuber, National Cancer Institute, Bethesda, MD
MONDAY, APRIL 16
10:45 a.m. to 11:45 a.m.
Presidential Address
The p53 Tumor Suppressor Pathway: From Genome Guardian to the Promise of Targeted Therapeutics
- Geoffrey M. Wahl, The Salk Institute for Biological Studies, La Jolla, CA
MONDAY, APRIL 16
12:30 p.m. to 1:30 p.m.
AACR Annual Business Meeting of Members
TUESDAY, APRIL 17
10:00 a.m. to 1:30 p.m.
Session on New Technology
Advances in Nanotechnology Applications for Cancer Research
Co-Chairpersons: Anna D. Barker, National Cancer Institute, Bethesda, MD, and Jan E. Schnitzer, Sidney Kimmel Cancer Center, San Diego, CA
- Update on the NCI alliance in nanotechnology for cancer, Anna D. Barker, National Cancer Institute, Bethesda, MD
- Integrated microsystems for multiplexed, high dynamic range cancer biomarker detection, Jongyoon Han, Massachusetts Institute of Technology, Cambridge, MA
- Using nanotechnology to map and target endothelium and its caveolae in vivo for solid tumor penetration and destruction, Jan E. Schnitzer, Sidney Kimmel Cancer Center, San Diego, CA
- Using dendrimer nanoparticles to enhance tumor chemotherapy, Francis C. Szoka, Jr., University of California, San Francisco, CA
- Combinatorial libraries of lipidoids for systemic siRNA delivery, Daniel G. Anderson, Massachusetts Institute of Technology, Cambridge, MA
- Sentinel lymph node detection with nanocrystals: Towards image-guided oncosurgery, Moungi G. Bawendi, Massachusetts Institute of Technology, Cambridge, MA
TUESDAY, APRIL 17
12:45 p.m. to 2:00 p.m.
Town Hall: Science Policy and Legislative Affairs
Cancer Funding Outlook in the New Congress
Co-Chairpersons: William G. Nelson, V, Johns Hopkins School of Medicine, Baltimore, MD, and Geoffrey M. Wahl, The Salk Institute for Biological Studies, La Jolla, CA
TUESDAY, APRIL 17
2:00 p.m. to 5:30 p.m.
Session to Commemorate the 50th Anniversary of the Discovery of Nitrosamine Carcinogenesis by P. N. Magee and J. M. Barnes
Dedicated to the memory of Christopher J. Michejda
Carcinogens in the Environment: Lessons Learned and Forgotten
Chairperson: Richard N. Loeppky, University of Missouri, Columbia, MO
- Nitrosamines in the environment: Are they still there?, Gerhard Eisenbrand, University of Kaiserslautern, Kaiserslautern, Germany
- Mechanistic studies on the formation and metabolism of nitrosamines, Richard N. Loeppky, University of Missouri, Columbia, MO
- From nitrosamines to nitric acid: The path to discovery, Steven R. Tannenbaum, Massachusetts Institute of Technology, Cambridge, MA
- Tobacco-specific nitrosamines: A problem that won’t go away, Stephen S. Hecht, University of Minnesota Cancer Center, Minneapolis, MN
TUESDAY, APRIL 17
2:00 p.m. to 5:30 p.m.
AACR/ International Psycho-Oncology Society/ American Psychosocial Oncology Symposium
Chemotherapy-related Cognitive Dysfunction: An Emerging Area of Translational Research
Chairperson: Jimmie C. Holland, Memorial Sloan-Kettering Cancer Center, New York, NY
- Clinical manifestations of cognitive dysfunction in patients receiving chemotherapy, Patricia A. Ganz, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
- Regional brain metabolism and blood flow changes in patients with chemotherapy-related cognitive deficits, Daniel Silverman, David Geffen School of Medicine, UCLA, Los Angeles, CA
- Cognitive dysfunction cytokines and other possible CNS mechanisms, Janette Vardy, Sydney Cancer Center, Concord, NSW, Australia
- Translational aspects of chemotherapy-related cognitive deficits, Sanne Schagen, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- Chemotherapy-related cognitive problems and possible genetic contributions, Tim A. Ahles, Memorial Sloan-Kettering Cancer Center, New York, NY